Article Sidebar
Published:
Jul 22, 2021Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Comparative efficacy and safety of pemetrexed and crizotinib in Chinese patients with advanced lung cancer: A preliminary clinical trial
Abstract
Purpose: To carry out a pilot clinical trial to compare the effectiveness and safety of crizotinib and pemetrexed-based regimens in Chinese patients with advanced lung cancer (ALC).
Method: Patients with confirmed diagnosis of ALC were randomly grouped and treated intravenously with a mixture of pemetrexed (500 mg/m2 ) and cisplatin (75 mg/m2 ) plus BSC, or crizotinib (250 mg BD) + BSC in a 1:1 ratio. Efficacy parameters such as overall survival (OS), objective response rate (ORR), and progression-free survival (PFS) were assessed after pemetrexed and crizotinib treatments. The safety of pemetrexed and crizotinib was determined. Survival time with respect to disease progression was also assessed.
Results: Pemetrexed-based regimens showed significantly higher OS and PFS than crizotinib (OS: median = 13.23 and 7.47 months, respectively; p < 0.001; PFS: median = 11.32 and 4.17 months, respectively). Objective response was also favorable in the patients treated with pemetrexed, when compared with those given crizotinib. Pemetrexed-based regimen was superior to crizotinib in improving OS, PFS and ORR, and it offered significantly greater clinical benefits than crizotinib in Chinese patients with ALC.
Conclusion: The results of clinical trial would help clinicians select appropriate therapeutic intervention for patients with ALC.
